EC Number   |
Expression |
Reference |
|---|
   1.1.1.62 | down |
application of medroxyprogestrone acetate, dydrogesterone and dienogest significantly decreases isoforms HSD17B1 and CYP19A1 expression and significantly increases isoform HSD17B2 expression. Dydrogesterone and dienogest also significantly suppress estrogen receptors ESR1 and ESR2 transcription, whereas medroxyprogestrone acetate and dydrogesterone significantly reduce mRNA levels of G protein-coupled estrogen receptor 1. Results thus suggest that in peritoneal endometriosis the beneficial effects of these progestins can be explained by lower HSD17B1 and higher HSD17B2 mRNA and protein levels, which lead to reduced local estradiol biosynthesis |
725827 |
| 1.1.1.62 | down |
endometrial 17beta-hydroxysteroid dehydrogenase activity is decreased on days 15-16 in pregnant and cyclic pigs compared with the preceding days |
762366 |
| 1.1.1.62 | down |
exposure to tributyltin chloride at 100 ng Sn2+/l causes a decrease in mRNA levels in digestive gland, after one and two months, while no effect is observed in gonads |
725829 |
| 1.1.1.62 | down |
HSD17B2 expression is reduced in breast cancer compared with benign tumors |
762074 |
| 1.1.1.62 | down |
miRNA-204-5p, 498, 205-3p and 579-3p reduce HSD17B2 expression |
762076 |
| 1.1.1.62 | down |
OxyR represses the expression of 17beta-hsd by its specific binding to the conserved motif of GATA-N9-TATC |
-, 760412 |
| 1.1.1.62 | up |
17beta-estradiol treatments increase HSD17B4 mRNA in the auditory region of males, which is contraryto findings in the song system |
740245 |
| 1.1.1.62 | up |
aromatase inhibitor treatment results in 17betaHSD1 upregulation in both A-549 and LK-87 cells |
740924 |
| 1.1.1.62 | up |
CrgA activates the expression of 17beta-hsd through its binding to the motif of T-N11-A |
-, 760412 |
| 1.1.1.62 | up |
dihydrotestosterone treatment increases HSD17B2 expression, with limited effect on HSD17B1 expression |
762076 |
